After pooling all included studies, a statistically significant improvement in OS was found for NSCLC patients with brain metastases with EGFR mutations compared with wild-type EGFR (HR: 0.73; 95% CI: 0.54–0.99; P = 0.045; Fig. 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.